Curran Simpson Regenxbio Inc. (RGNX) insider trading activity

Curran Simpson is Chief Executive Officer of REGENXBIO Inc.. Currently has a direct ownership of 216,162 shares of RGNX, which is worth approximately $2.49 Million. The most recent transaction as insider was on Oct 09, 2025, when has been sold 20,811 shares (Common Stock) at a price of $12.62 per share, resulting in proceeds of $262,634. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 216K

14.33% 3M change

27.13% 12M change

Total Value Held $2.49 Million

Curran Simpson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 09 2025	SELL Open market or private sale	$262,634 $12.62 p/Share	20,811 Reduced 8.78%	216,162 Common Stock
Sep 29 2025	SELL Open market or private sale	$76,468 $10.03 p/Share	7,624 Reduced 3.12%	236,973 Common Stock
Sep 10 2025	SELL Open market or private sale	$77,494 $10.02 p/Share	7,734 Reduced 3.07%	244,597 Common Stock
Jul 01 2025	SELL Payment of exercise price or tax liability	$38,689 $8.23 p/Share	4,701 Reduced 1.83%	252,331 Common Stock
Jan 02 2025	SELL Payment of exercise price or tax liability	$92,118 $7.73 p/Share	11,917 Reduced 7.01%	158,120 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	-	98,912 Added 27.79%	257,032 Common Stock
Aug 01 2024	SELL Open market or private sale	$1,500 $15.0 p/Share	100 Reduced 0.06%	170,037 Common Stock
Jul 29 2024	SELL Open market or private sale	$145,105 $15.04 p/Share	9,648 Reduced 5.37%	170,137 Common Stock
Jul 01 2024	BUY Grant, award, or other acquisition	-	56,458 Added 23.9%	179,785 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$145,754 $17.95 p/Share	8,120 Reduced 8.73%	84,865 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	38,462 Added 23.77%	123,327 Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$47,083 $22.68 p/Share	2,076 Reduced 7.66%	25,040 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	67,945 Added 42.22%	92,985 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	10,700 Added 28.29%	27,116 Common Stock
Jan 01 2022	SELL Payment of exercise price or tax liability	$43,556 $32.7 p/Share	1,332 Reduced 7.51%	16,416 Common Stock
Jan 14 2021	SELL Open market or private sale	$580,716 $50.01 p/Share	11,612 Reduced 39.55%	17,748 Common Stock
Jan 14 2021	BUY Exercise of conversion of derivative security	$321,072 $27.65 p/Share	11,612 Added 28.34%	29,360 Common Stock
Jan 12 2021	SELL Open market or private sale	$85,051 $50.03 p/Share	1,700 Reduced 8.74%	17,748 Common Stock
Jan 12 2021	BUY Exercise of conversion of derivative security	$33,150 $19.5 p/Share	1,700 Added 8.04%	19,448 Common Stock
Jan 07 2021	SELL Open market or private sale	$259,302 $50.01 p/Share	5,185 Reduced 22.61%	17,748 Common Stock
Jan 07 2021	BUY Exercise of conversion of derivative security	$101,108 $19.5 p/Share	5,185 Added 18.44%	22,933 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	13,800 Added 43.74%	17,748 Common Stock

Curran Simpson

Chief Executive Officer

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGNX shares.

Notify only if

Value

Insider Trading

Get notified when an Regenxbio Inc. insider buys or sells RGNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENXBIO Inc.

Track Activities on RGNX

Account